Skip to main content

Side Menu Card

Sarah McCague, MS

Sarah McCague, MS

Sarah McCague, MS

Sarah McCague, MS, is the Administrative Manager of Clinical In Vivo Gene Therapy at Children's Hospital of Philadelphia.


267-426-7771

About Sarah McCague, MS

Titles

Administrative Manager

Awards and Honors

2018, Academic Excellence Award, Drexel University College of Medicine

Education & training

Undergraduate Degree

BA - Middlebury College, Middlebury, VT

Graduate Degree

MS in Clinical Research Organization and Management - Drexel University College of Medicine, Philadelphia, PA

Team affiliations

View fewer all team affiliations View all all team affiliations

Publications

Publications

2019

Chung, D.C., Bertelsen, M., Lorenz, B., Pennesi, M.E., Leroy, B.P., Hamel, C.P., Pierce, E., Sallum, J., Larsen, M., Stieger, K., Preising, M., Weleber, R., Yang, P., Place, E., Liu, E., Schaefer, G., DiStefano-Pappas, J., Elci, O.U., McCague, S., Wellman, J.A., High K.A., Reape K.Z. (2019) The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene. Am J Ophthalmol. 199, 58-70.

Maguire, A.M., Russell, S., Wellman, J.A., Chung, D.C., Yu, Z.F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K.A., McCague, S.,… Bennett, J. (2019) Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology, 126(9), 1273-1285.

2017

Chung, D.C., McCague, S., Yu, Z-F., Thill, S., DiStefano-Pappas, J., Bennett, J., … High, K.A. (2017) Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clinical & Experimental Ophthalmology, 2017 August 31.

Russell, S., Bennett, J., Wellman, J.A., Chung, D.C., Yu, Z-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., … Maguire, A.M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. The Lancet, 390(10097), 849-860.

2016

Bennett, J., Wellman, J., Marshall, K.A., McCague, S., Ashtari, M., DiStefano-Pappas, J., … Maguire, A.M. (2016). Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: A follow-on phase 1 trial. The Lancet, 388(10045), 661-672.

2015

McCague, S., Wellman, J., Yu, F., Thill, S., DiStefano-Pappas, J., Bennett, J., … Chung, D.C. Mobility testing validation study – Using a novel, standardized mobility test to evaluate functional vision in patients with inherited retinal degeneration. Poster presented at: Association for Research in Vision and Ophthalmology Annual Meeting; 2015 May 3-7; Denver, CO.

2012

Bennett, J., Ashtari, M., Wellman, J., Marshall, K.A., Cyckowski, L.L., Chung, D.C., McCague, S., … Maguire, A.M. (2012). AAV2 gene therapy readministration in three adults with congenital blindness. Science Translational Medicine, 4(120), 120ra15.

Jump back to top